Abingworth LLP Aeglea Bio Therapeutics, Inc. Transaction History

Abingworth LLP

  • $301 Million
  • Q4 2022

A detailed history of Abingworth LLP transactions in Aeglea Bio Therapeutics, Inc. stock. As of the latest transaction made, Abingworth LLP holds 240,500 shares of AGLE stock, worth $6.65 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
240,500
Previous 240,500 -0.0%
Holding current value
$6.65 Million
Previous $127,000 14.96%
% of portfolio
0.04%
Previous 0.04%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019
BUY
$7.6 - $9.4 $1.83 Million - $2.26 Million
240,500 New
240,500 $1.93 Million

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0
View Full List

About Aeglea BioTherapeutics, Inc.

AGLE Quotes by TradingView
  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email